Theravance Biopharma, Inc.
Expected move
No implied move.
Next report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Theravance Biopharma, Inc.
17.04
−0.12%
vs ±6.0% implied · ×0.02
shaded = implied · ▲▼ = realized
Linked news
Theravance Biopharma has 3 disclosed suppliers and 5 disclosed customers in SEC filings.
SentenceSince its formation, the Committee has been working on an ongoing basis with Lazard, its independent financial advisor, to evaluate opportunities available to us, including under multiple potential outcomes for our Phase 3 CYPRESS study of ampreloxetine in patients with neurogenic orthostatic hypotension due to multiple system atrophy.
SentenceInterest expense in 2025 and 2024 represented non-cash interest expense associated with $25.0 million received from Royalty Pharma in July 2022 to partially fund our CYPRESS study.
TBPH 10-Kaccession 0001104659-26-033077
SentencePrior to the sale of VIBATIV to Cumberland Pharmaceuticals Inc. ("Cumberland") in November 2018, we had certain price reporting obligations to the Medicaid Drug Rebate program and other governmental pricing programs, and we had obligations to report average sales price under the Medicare program.
TBPH 10-Kaccession 0001104659-26-033077
SentenceThrough the milestone payment we may receive from Royalty Pharma if certain TRELEGY global net sales thresholds are met following our sale of our economic interest in TRELEGY (the "Milestone Payments"), we may participate economically in royalty payments from GSK with respect to the TRELEGY.
TBPH 10-Kaccession 0001104659-26-033077